Bexson Biomedical Inc. is developing a small wearable device that could allow users to control their psychedelic experiences from home.
The device attaches to the stomach and releases psychedelic compounds into a layer of fat via a tiny needle. In theory, users will be prescribed the pre-calibrated device and be able to use it in the comfort of their home. Users can preprogram the intensity and duration of the trip and potentially adjust the dose and rate of infusion throughout the trip.
This administration method would produce more consistent results across patients than oral administration, which can produce varying results due to differences in liver enzymes.
The device is currently being developed to administer ketamine for chronic pain, but could also be used for psilocybin, LSD, and DMT.